Skip to main content

RT @RichardPAConway: Flatman et al. Risk of infections in children with third trimester TNFi use, high vs low (CTZ, ETN)

Social Author Name
Richard Conway
Tweet Content
Flatman et al. Risk of infections in children with third trimester TNFi use, high vs low (CTZ, ETN) placental transfer. No difference but wide CIs, aHR 0.98 (0.36, 2.61) @RheumNow #ACR22 Abstr#2192 https://t.co/350UxX9bkL https://t.co/29uOtek8w7

RT @AurelieRheumo: 💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks Insom

Social Author Name
Aurelie Najm
Tweet Content
💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks Insomnia Severity Index -9.8 RAID -1.4 PGA -13 Small sample size wk6 trend improvement sleep efficiency 89% vs84% p=0.07 but not wk26 https://t.co/rpKdtbREYs Abs#2188 #ACR22 @RheumNow https://t.co/kEBcPAdIKW

RT @uptoTate: Interesting Abs 1997 finds butyrate supplementation in RA assoc'd w/changes in human gut microbiota compos

Social Author Name
Dr. Rachel Tate
Tweet Content
Interesting Abs 1997 finds butyrate supplementation in RA assoc'd w/changes in human gut microbiota composition and in peripheral Treg abundance and markers of Treg activation. More data needed to determine clinical/dz activity relevence. #ACR22 @RheumNow https://t.co/tQocYUU0Er

RT @bella_mehta: #PregnantWoman with #sle - n = 873 Highest overall adverse events in Preexisting HTN complicated by ra

Social Author Name
Bella Mehta
Tweet Content
#PregnantWoman with #sle - n = 873 Highest overall adverse events in Preexisting HTN complicated by race We have a Modifiable risk factor - HTN to work closely abst#2107 @rheumnow #ACR22 #ACRBest https://t.co/EC8c7Dzrvs https://t.co/Jydz0uo1bv

RT @AurelieRheumo: Interosseous tendon inflammation (ITI) the new predictor of clinical RA in pts w/ clinically suspect

Social Author Name
Aurelie Najm
Tweet Content
Interosseous tendon inflammation (ITI) the new predictor of clinical RA in pts w/ clinically suspect arthralgia. 600+ pts Hands MRI Present 10% pts w/ CSA, 1% symptom free 27% ACPA+ 7% ACPA- HR 4.5 dvlpmt of clinical RA https://t.co/BmRF1tLFx9 Abs#2204 #ACR22 @RheumNow https://t.co/F8DUxiI2dh

RT @ericdeinmd: Thieves Market #ACR22 Amoebic arthritis - is it rare? Case from Indonesia After the case, found it in 3

Social Author Name
Eric Dein
Tweet Content
Thieves Market #ACR22 Amoebic arthritis - is it rare? Case from Indonesia After the case, found it in 3 other synovial fluids! Rx with surgery, metronidazole - later rx for post-ifn arthritis and gout @RheumNow https://t.co/oi8PqtTTyc

RT @bella_mehta: Severe subtype of #sJIA HLADRB1*15:01 known to be associated with adverse drug reactions to biologics.

Social Author Name
Bella Mehta
Tweet Content
Severe subtype of #sJIA HLADRB1*15:01 known to be associated with adverse drug reactions to biologics. prospective cohort - 65pts. - Anakinra effective irrespective of HLADRB1*15:01 - No difference in eosinophilia - Recommend not to wait to start tx @rheumnow #ACR22 abst#L12 https://t.co/LX5lMJOKRf

RT @AurelieRheumo: Alert 🚨 New imaging technology MSOT = combination of US and photo acoustic imaging Detects metab

Social Author Name
Aurelie Najm
Tweet Content
Alert 🚨 New imaging technology MSOT = combination of US and photo acoustic imaging Detects metabolites in enthesis and synovitis 🫱🏼>Hb and O2 saturation correlate w/ Doppler+ 🫱🏼>Hb & collagen correlate w/ calcifications https://t.co/X18fGFVh5L Abs#2205 #ACR22 @RheumNow https://t.co/84BU5YUrCz

RT @drdavidliew: RA really does still impact employment outcomes for many, despite T2T. @earlyarthritis🇨🇦 data in

Social Author Name
David Liew
Tweet Content
RA really does still impact employment outcomes for many, despite T2T. @earlyarthritis🇨🇦 data in working age people show many back in the game in the first year, but not many more after that. Plenty more to do to get all our pts back to their best! ABST1967 #ACR22 @RheumNow https://t.co/isD1rgkFoH

RT @RHEUMarampa: SURPASS was a head-to-head study comparing SEC vs ADA biosimilar (SDZ-ADL) in r-axSpA on spinal radio p

Social Author Name
sheila
Tweet Content
SURPASS was a head-to-head study comparing SEC vs ADA biosimilar (SDZ-ADL) in r-axSpA on spinal radio progression: Results showed no significant diff in spinal radio progression bet. the 2 grps. Biosimilars remain tx options for r-axSpA. #ACR22 @RheumNow ABST#L15
Subscribe to
×